Published in Volume
119, Issue 10 (October 1, 2009)
J Clin Invest. 2009;119(10):2848–2848.
doi:10.1172/JCI41037.
Copyright © 2009, American Society for Clinical
Investigation. Published under the Creative Commons Attribution-No Derivative Works
3.0 License (United States)
Personal Perspective
Healing health care
Elizabeth M. McNally
The University of Chicago, Chicago, Illinois, USA. E-mail:
emcnally@uchicago.edu.
First published September 10, 2009
By 2018, health care expenditures are expected to consume more than 20% of US
gross domestic product (1). Over the last decade,
there has been a marked increase in health care spending without corresponding improvements
in longevity or quality of life. In short, we simply are not getting our
money’s worth, and we need to improve the value of our health care dollar.
Reduce or eliminate direct-to-consumer advertising.
My healthy seven-year-old niece complained that her bones were sore and she
needed Boniva (once-monthly oral ibandronate). In the United States, health care
advertising is pervasive and has become part of the fabric of everyday life. The most
dramatic increases in health care spending have been since 1997, the year the FDA relaxed
regulation on direct-to-consumer advertising on television. From 1997 to 2007,
direct-to-consumer advertising for prescription drugs increased 330% (2). In 2005, the budget for prescription drug advertising was $30
billion. Notably, this cost estimate does not include advertising for hospitals, insurers,
devices, and other health-related services, and it does not include the costs of
unnecessary visits and testing. Direct-to-consumer advertising of prescription drugs is
having long-term consequences on the pharmaceutical industry, steering business strategy
toward “lifestyle” drugs and away from the more difficult-to-treat
diseases such as heart disease, cancer, and diabetes. Research is needed to devise new
strategies for these disorders, and the budget for research should index to health care
expenditures. A redirection of the direct-to-consumer advertising budget toward research
would be a better investment in our future. Ironically, an additional $45–$60
million has been spent this year on advertising for health care reform (3). The winners are clearly the advertising companies,
and the losers are those who have to explain to their children what erectile dysfunction is
and why drugs are so expensive.
Toss out exclusions for preexisting conditions.
Insurance providers would like to screen and exclude those who are ill and those
who are at risk of becoming ill, since providing for the healthy is a better business
strategy. I am a geneticist, and we now routinely use genetic diagnoses to guide clinical
management and predict risk for future disease. Advances in human genetics are obliterating
the concept of the preexisting condition, since all human disease has a heritable
component. The ability to predict risk for disease is advancing at light speed. Such
genetic research can nearly instantaneously be converted to clinical testing, where it
usefully predicts risk of disease, the insurers’ dream come true. The Genetic
Information Nondiscrimination Act (GINA) took a first step toward protecting against
insurance discrimination based on genotype (4).
Treating a genetic condition is not protected under GINA. There is an increasingly blurry
line between an “at-risk” genotype versus early-phase disease that
requires therapy to reduce risk. The greatest advances of this decade are deriving from the
fruits of the human genome project. Curiously, coverage for genetic testing is still
limited, and early-phase risk reduction therapy is not always covered. Eliminating an
insurer’s ability to void coverage of a preexisting condition has been
extensively discussed in the context of health care reform. The insurance industry is
politically mighty; it is up to the public to keep pressure on members of Congress to
legislate protection against the preexisting condition exclusion.
Bring health information management into the modern era.
One of the biggest money pits for our health care dollars is the outdated
management of health information. The electronic information age arrived some time ago but
left health information behind. Health information is stored in a variety of formats that
are often incompatible, ranging from paper to obsolete electronic media. Health care
providers do not share information readily with each other. Sharing information is time
consuming and a largely uncompensated activity. It is far easier to reorder a test than to
request the results from the test that has already been performed. A uniform format for
health care information should be established and used. Information management and
maintenance should be taken from the control of the health providers and given to
organizations with expertise in information management. Patients should control who has
access to their personal health information. It should be within a patient’s
right to authorize or deauthorize access to health information. Patients should be able to
readily determine who has accessed their heath information and for what purpose. Health
care providers should not “own” patients’ health
information. Diagnostic testing increasingly relies on imaging, and while I can watch just
about anything on YouTube, I frequently cannot view my patients’
echocardiograms performed at outside institutions. Having a uniform format would allow
ready access and viewing, which would result in better health care, improved quality
control, and a reduction in unnecessary testing. It is time for health care information to
grow up and at least be as good as iTunes. Health care providers have repeatedly
demonstrated an inadequacy in this area, and it seems a striking opportunity for the
business community to design and implement a new approach to this problem.
Footnotes
J. Clin. Invest.
119:2848 (2009). doi: 10.1172/JCI41037.
References
-
Centers for Medicare and Medicaid Services. National health expenditure
data overview.
http://www.cms.hhs.gov/nationalhealthexpenddata/01_overview.asp .
-
Donohue, J.M., Cevasco, M., Rosenthal, M.B. 2007. A decade of direct-to-consumer advertising of prescription drugs. N. Engl. J. Med. 357:673-681.
-
Campaign Media Analysis Group.
http://www.tnsmi-cmag.com/index.asp .
-
Anonymous. 2008. Genetic Information Nondiscrimination Act. HR 493. 110th Congress, 2nd
sess. Congr. Rec. (Dly. Ed.). 154:D661.